Question 23

Sitagliptin (Januvia) is a drug used in the treatment of type 2 diabetes.

Sitagliptin, marketed as Januvia, is specifically indicated for the management of type 2 diabetes mellitus. It works by enhancing the body's own ability to lower blood sugar levels after meals.

A) schizophrenia.

Sitagliptin is not indicated for the treatment of schizophrenia. Schizophrenia is a psychiatric disorder that requires antipsychotic medications, not diabetes medications like sitagliptin.

B) Parkinson's disease.

Sitagliptin does not treat Parkinson's disease, which is a neurodegenerative disorder that affects movement. The management of Parkinson's typically involves dopaminergic medications, making sitagliptin irrelevant for this condition.

C) type 2 diabetes.

Sitagliptin is indeed used for the treatment of type 2 diabetes. It functions as a DPP-4 inhibitor, which helps to increase insulin production and decrease glucose production in the liver, thereby effectively managing blood sugar levels in patients with this condition.

D) type 1 diabetes.

Sitagliptin is not appropriate for the treatment of type 1 diabetes. Type 1 diabetes is an autoimmune condition that requires insulin therapy, as the body does not produce insulin, unlike type 2 diabetes where insulin resistance is the primary issue.

Conclusion

Sitagliptin's role as a treatment for type 2 diabetes is well established, as it directly targets the mechanisms involved in insulin regulation and blood glucose control. In contrast, the other options represent conditions that require different therapeutic approaches, thus reinforcing that sitagliptin is specifically designed for managing type 2 diabetes.